93 related articles for article (PubMed ID: 8625192)
21. HFE genotype in patients with hemochromatosis and other liver diseases.
Bacon BR; Olynyk JK; Brunt EM; Britton RS; Wolff RK
Ann Intern Med; 1999 Jun; 130(12):953-62. PubMed ID: 10383365
[TBL] [Abstract][Full Text] [Related]
22. Searching for hereditary hemochromatosis.
Laudicina RJ
Clin Lab Sci; 2006; 19(3):174-83. PubMed ID: 16910235
[TBL] [Abstract][Full Text] [Related]
23. Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia.
Solanas-Barca M; Mateo-Gallego R; Calmarza P; Jarauta E; Bea AM; Cenarro A; Civeira F
J Clin Endocrinol Metab; 2009 Nov; 94(11):4391-7. PubMed ID: 19820015
[TBL] [Abstract][Full Text] [Related]
24. Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry.
Kowdley KV; Brandhagen DJ; Gish RG; Bass NM; Weinstein J; Schilsky ML; Fontana RJ; McCashland T; Cotler SJ; Bacon BR; Keeffe EB; Gordon F; Polissar N;
Gastroenterology; 2005 Aug; 129(2):494-503. PubMed ID: 16083706
[TBL] [Abstract][Full Text] [Related]
25. Genotype screening for hereditary hemochromatosis among voluntary blood donors in Hungary.
Andrikovics H; Kalmár L; Bors A; Fandl B; Petri I; Kalász L; Tordai A
Blood Cells Mol Dis; 2001; 27(1):334-41. PubMed ID: 11358395
[TBL] [Abstract][Full Text] [Related]
26. Blood lead concentrations in hereditary hemochromatosis.
Barton JC; Patton MA; Edwards CQ; Griffen LM; Kushner JP; Meeks RG; Leggett RW
J Lab Clin Med; 1994 Aug; 124(2):193-8. PubMed ID: 8051482
[TBL] [Abstract][Full Text] [Related]
27. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
28. Cancer risks in BRCA2 mutation carriers.
Breast Cancer Linkage Consortium
J Natl Cancer Inst; 1999 Aug; 91(15):1310-6. PubMed ID: 10433620
[TBL] [Abstract][Full Text] [Related]
29. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.
Smith BC; Gorve J; Guzail MA; Day CP; Daly AK; Burt AD; Bassendine MF
Hepatology; 1998 Jun; 27(6):1695-9. PubMed ID: 9620344
[TBL] [Abstract][Full Text] [Related]
30. Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients.
Santos PC; Cançado RD; Pereira AC; Schettert IT; Soares RA; Pagliusi RA; Hirata RD; Hirata MH; Teixeira AC; Figueiredo MS; Chiattone CS; Krieger JE; Guerra-Shinohara EM
Blood Cells Mol Dis; 2011 Apr; 46(4):302-7. PubMed ID: 21411349
[TBL] [Abstract][Full Text] [Related]
31. Integrin beta3 Leu33Pro homozygosity and risk of cancer.
Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
J Natl Cancer Inst; 2003 Aug; 95(15):1150-7. PubMed ID: 12902444
[TBL] [Abstract][Full Text] [Related]
32. Iron-overload-related disease in HFE hereditary hemochromatosis.
Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
[TBL] [Abstract][Full Text] [Related]
33. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load.
Carroll GJ; Breidahl WH; Bulsara MK; Olynyk JK
Arthritis Rheum; 2011 Jan; 63(1):286-94. PubMed ID: 20954257
[TBL] [Abstract][Full Text] [Related]
34. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.
Merryweather-Clarke AT; Cadet E; Bomford A; Capron D; Viprakasit V; Miller A; McHugh PJ; Chapman RW; Pointon JJ; Wimhurst VL; Livesey KJ; Tanphaichitr V; Rochette J; Robson KJ
Hum Mol Genet; 2003 Sep; 12(17):2241-7. PubMed ID: 12915468
[TBL] [Abstract][Full Text] [Related]
35. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis.
Bardou-Jacquet E; Morcet J; Manet G; Lainé F; Perrin M; Jouanolle AM; Guyader D; Moirand R; Viel JF; Deugnier Y
J Hepatol; 2015 Mar; 62(3):682-9. PubMed ID: 25450707
[TBL] [Abstract][Full Text] [Related]
36. The CD8+ T-lymphocyte profile as a modifier of iron overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y homozygous subjects.
Cruz E; Melo G; Lacerda R; Almeida S; Porto G
Blood Cells Mol Dis; 2006; 37(1):33-9. PubMed ID: 16762569
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation.
Shaheen NJ; Bacon BR; Grimm IS
Hepatology; 1998 Aug; 28(2):526-9. PubMed ID: 9696020
[TBL] [Abstract][Full Text] [Related]
38. Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis.
Press RD; Flora K; Gross C; Rabkin JM; Corless CL
Am J Clin Pathol; 1998 May; 109(5):577-84. PubMed ID: 9576576
[TBL] [Abstract][Full Text] [Related]
39. Cancer risk in heterozygotes for ataxia-telangiectasia.
Geoffroy-Perez B; Janin N; Ossian K; Laugé A; Croquette MF; Griscelli C; Debré M; Bressac-de-Paillerets B; Aurias A; Stoppa-Lyonnet D; Andrieu N
Int J Cancer; 2001 Jul; 93(2):288-93. PubMed ID: 11410879
[TBL] [Abstract][Full Text] [Related]
40. HFE based re-evaluation of heterozygous hemochromatosis.
Moirand R; Guyader D; Mendler MH; Jouanolle AM; Le Gall JY; David V; Brissot P; Deugnier Y
Am J Med Genet; 2002 Sep; 111(4):356-61. PubMed ID: 12210292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
